Gollob Jared 4
4 · Kymera Therapeutics, Inc. · Filed Oct 15, 2025
Insider Transaction Report
Form 4
Gollob Jared
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-10-15$60.37/sh−29,264$1,766,668→ 140,304 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-15−22,210→ 0 totalExercise: $2.08Exp: 2029-05-22→ Common Stock (22,210 underlying) - Exercise/Conversion
Common Stock
2025-10-15$1.31/sh+28,999$37,989→ 147,358 total - Sale
Common Stock
2025-10-15$61.49/sh−8,963$551,161→ 131,341 total - Sale
Common Stock
2025-10-15$63.09/sh−6,453$407,099→ 109,992 total - Exercise/Conversion
Common Stock
2025-10-15$2.08/sh+22,210$46,197→ 169,568 total - Sale
Common Stock
2025-10-15$62.72/sh−14,896$934,326→ 116,445 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-15−28,999→ 0 totalExercise: $1.31Exp: 2028-10-31→ Common Stock (28,999 underlying)
Footnotes (6)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.01 to $62.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.01 to $63.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.02 to $63.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The shares underlying this stock option are fully vested and exercisable.